2026 Q2 Portfolio Activity
In 2026 Q2, Fairmount Funds Management LLC maintained a portfolio of 13 distinct positions. The most significant new addition was FAETH THERAPEUTICS INC, now representing 1.19% of the total fund value. They heavily accumulated shares in VIRIDIAN THERAPEUTICS INC, increasing the position by 30.1%. Conversely, Fairmount Funds Management LLC completely exited their position in SPYRE THERAPEUTICS INC.
Position History
hover any row below to update
Loading…
Total Positions
13
Quarter
2026 Q2
Top Holding
ORKA (23.3%)
Top 10 Concentration
97.6%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-13 of 13
Fairmount Funds Management LLC Full Holdings List — 2026 Q2
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
ORKA
ORUKA THERAPEUT...
|
Healthcare | 23.31% | 13.13% |
#1
4
Prev: #5
|
7.0 |
—
|
no change | no change |
P
S
|
3,705,262 | $352,629,785 | 2024 Q3 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
DNTH
DIANTHUS THERAP...
|
Healthcare | 16.35% | 15.38% |
#2
Prev: #2
|
6.5 |
—
|
no change | no change |
P
S
|
2,537,191 | $247,325,379 | 2023 Q3 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
GLTO
DAMORA THERAPEU...
|
Healthcare | 14.98% | 16.30% |
#3
2
Prev: #1
|
6.0 |
—
|
no change | no change |
P
S
|
8,713,000 | $226,625,130 | 2026 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
COGT
COGENT BIOSCIEN...
|
Healthcare | 14.08% | 15.30% |
#4
1
Prev: #3
|
5.5 |
—
|
no change | no change |
P
S
|
5,503,418 | $212,982,277 | 2020 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
JBIO
JADE BIOSCIENCE...
|
Healthcare | 6.69% | 4.62% |
#5
3
Prev: #8
|
4.2 |
—
|
no change | no change |
P
S
|
4,553,494 | $101,178,637 | 2025 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
ELVN
ENLIVEN THERAPE...
|
Healthcare | 6.22% | 5.25% |
#6
1
Prev: #7
|
3.5 |
—
|
no change | no change |
P
S
|
1,855,644 | $94,173,933 | 2023 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
VRDN
VIRIDIAN THERAP...
|
Healthcare | 6.18% | 5.53% |
#7
1
Prev: #6
|
5.0 |
—
|
1,176,470 | 30.1% |
P
S
|
5,090,928 | $93,520,347 | 2021 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
ZBIO
ZENAS BIOPHARMA...
|
Healthcare | 3.96% | 3.33% |
#8
2
Prev: #10
|
2.6 |
—
|
no change | no change |
P
S
|
2,359,025 | $59,872,055 | 2024 Q3 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
N/A
CRESCENT BIOPHA...
|
|
Unknown | 3.27% | 3.65% |
#9
Prev: #9
|
2.3 |
—
|
no change | no change |
P
S
|
2,747,866 | $49,461,588 | — | 13F Filing | 2026-06-30 | 2026-08-14 | ||
|
APGE
APOGEE THERAPEU...
|
Healthcare | 2.62% | 1.82% |
#10
1
Prev: #11
|
2.0 |
—
|
no change | no change |
P
S
|
298,647 | $39,639,416 | 2023 Q3 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
SNSE
FAETH THERAPEUT...
|
Healthcare | 1.19% | — |
#11
Prev: #—
|
4.0 |
—
|
722,020 | — |
NEW
|
722,020 | $18,050,500 | 2026 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
IKT
INHIBIKASE THER...
|
Healthcare | 1.16% | 1.05% |
#12
Prev: #12
|
1.5 |
—
|
no change | no change |
P
S
|
8,625,000 | $17,508,750 | 2024 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
SYRE
SPYRE THERAPEUT...
|
Healthcare | 0.00% | 14.64% |
Sold All 😨
(Was: #4) |
0.0 |
—
|
-4,018,101 | -100.0% |
CLOSED
|
— | $— | 2023 Q3 | 13F Filing | 2026-06-30 | 2026-08-14 |
Showing 1-13 of 13 holdings